AzTrials
AzTrials

Severe SpasticityPhase 4SISTERSNCT01032239

SISTERS: Spasticity In Stroke Study - Randomized Study

A Phase 4 study testing intrathecal baclofen in people with Severe Spasticity, run by MedtronicNeuro at 25 sites in 9 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To demonstrate that Intrathecal Baclofen (ITB) Therapy, compared to Best Medical Treatment (BMT), has superior efficacy in the treatment of severe spasticity in adult post-stroke patients with generalized spastic hypertonia who have not reached their therapy goal with other treatment interventions assessed by a… Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Severe Spasticity
What is being tested?
intrathecal baclofen
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
61 participants
Where
25 sitesin 9 countries
Study dates
Nov 2009to Sep 2016
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • To be eligible for inclusion into this study, patients must fulfill all of the following criteria prior to study enrollment:
  • patient (or legal guardian) has been informed of the study procedures and has given written informed consent
  • patient experienced last stroke > 6 months prior to enrollment
  • patient presents spasticity in at least 2 extremities
  • patient presents an Ashworth score ≥ 3 in a minimum of two of the affected muscle groups in the lower extremities
  • patient is eligible to receive ITB Therapy following the Adult Spasticity Algorithm. A patient does not reach his/her therapy goal with other treatment interventions
Show all 9Show fewer
  • stable blood pressure: no change in hypertensive medication in last month (NOTE: ventriculoperitoneal shunts and valves can be present)
  • if female, she must either be post-menopausal or surgically sterilized; or use a hormonal contraceptive, intrauterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study
  • patient/family is willing to comply with study protocol including attending the study visits

Who cannot join

  • To be eligible for inclusion in this study the patients must not meet any of the following criteria:
  • patient/family is considered by the physician to be unable or unwilling to participate in long-term ITB Therapy management
  • patient has known hypersensitivity to baclofen
  • active systemic infection (NOTE: pressure sores are not a contraindication unless they are present near the implant sites)
  • presence of a cardiac pacemaker, ICD, implantable neurostimulator or drug delivery device
  • uncontrolled refractory epilepsy
Show all 9Show fewer
  • use of oral vitamin K antagonists, e.g. warfarin/coumadin; unless the patient can switch to another accepted anticoagulant (e.g. heparin, aggrenox, fragmin, plavix, ticlid) for the period of ITB test and implant
  • patient is pregnant or breastfeeding
  • patient received a Botulinum toxin injection less than 4 months ago

Trial locations and contacts

25 sites in 9 countries.

25 sites in 9 countries

United States9 sites
  • Saint Alphonsus Regional Med Center

    Boise, Idaho, 83704

  • Design Neuroscience Center

    Doral, Florida, 33172

  • Einstein Hospital/Moss Rehabilitation

    Elkins Park, Pennsylvania, 19027-2220

  • TIRR Memorial Herman Hospital

    Houston, Texas, 77030

  • University of California Irvine

    Irvine, California, 92697

  • Research Medical Center

    Kansas City, Missouri, 64132

  • Rehabilitation Medical Group - Florida Hospital

    Orlando, Florida, 32806

  • Tallahassee Neurological Clinic Department of Neurosurgery

    Tallahassee, Florida, 32308

  • MedStar National Rehabilitation Network

    Washington D.C., District of Columbia, 20010

Other trials in United States

Germany4 sites
  • Kliniken Beelitz GmbH Neurologische Rehabilitationsklinik

    Beelitz-Heilstätten, 14547

  • Ambulantes Neurologisches Rehabilitationszentrum

    Bonn, 53117

  • Therapiezentrum Burgau

    Burgau, 89331

  • Rhein-Sieg-Klinik Dr. Becker Klinikgesellschaft

    Nümbrecht, 51588

Other trials in Germany

Belgium3 sites
  • Clin. Univ. UCL Saint Luc

    Brussels, 1200

  • Universitair Ziekenhuis Gent

    Ghent, 9000

  • Universitaire Ziekenhuizen Leuven, campus Pellenberg

    Leuven, B-3000

Other trials in Belgium

Austria2 sites
  • Sozialmedizinisches Zentrum Baumgartner Höhe Otto-Wagner-Spital

    Vienna, 1140

  • Landeskrankenhaus Hochzirl

    Zirl, 6170

Other trials in Austria

Italy2 sites
  • Centro di Riabilitazione "Villa Beretta"

    Costa Masnaga, 23845

  • Fondazione Salvatore Maugeri Clinica del lavoro e della riabilitazione IRCSS

    Pavia, 27100

Other trials in Italy

Spain2 sites
  • Fundació Privada Institut de Neurorehabilitació Guttmann, Badalona

    Barcelona, 08916

  • Hospital Universitario La Paz

    Madrid, 28046

Other trials in Spain

Netherlands1 site
  • Afdeling Revalidatie Academisch Ziekenhuis Maastricht

    Maastricht, 6229

Other trials in Netherlands

Slovenia1 site
  • Univerzitetni rehabilitacijski inštitut Republike Slovenije Soča

    Ljubljana, 1000

Other trials in Slovenia

United Kingdom1 site
  • St George's Hospital

    London, SW17 0 QT

Other trials in United Kingdom

About this study

Official title: A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment

To demonstrate that Intrathecal Baclofen (ITB) Therapy, compared to Best Medical Treatment (BMT), has superior efficacy in the treatment of severe spasticity in adult post-stroke patients with generalized spastic hypertonia who have not reached their therapy goal with other treatment interventions assessed by a decrease in the average Ashworth Scale (AS) score in the lower extremities.

Read the detailed description

This is a randomized, controlled open-label parallel group study to demonstrate the efficacy benefit of ITB Therapy over BMT in post-stroke patients with severe spasticity who have not reached their therapy goal with other treatment interventions.

In order to evaluate the efficacy benefit of ITB Therapy over BMT in post-stroke patients, a two-arm parallel group design will be applied. Patients will be equally randomized to one of two treatment arms:

  1. ITB Therapy arm; or
  2. BMT arm

The study consists of a run-in phase of 21 days for the BMT treatment arm and 2-25 days for the ITB Therapy treatment arm, followed by a 6 month active trial.

The BMT treatment arm will receive a combination of oral antispastic medication and physiotherapy. Patients must be prescribed at least one or a combination of the following oral antispastic medications: oral baclofen, tizanidine, diazepam (or other benzodiazepines) or dantrolene. Following the run-in phase, patients will enter the 6 month active trial.

The ITB Therapy treatment arm will receive a combination of ITB Therapy and physiotherapy. During the run-in phase, a test with intrathecal baclofen will be performed to evaluate the response of the patient. Patients fulfilling the test success criterium will be implanted with a Medtronic SynchroMed®II infusion system. Following implant, patients will enter into the 6 month active trial, which includes a 6 week titration phase, during which time oral antispastic medications must be gradually reduced with complete discontinuation by the end of the titration period.

During the 6 month active trial, patients will be assessed at 3 and 6 months. All primary and secondary endpoint assessments will be performed by a blinded assessor.

The total study duration is expected to be 60 months, including a 39 month enrollment period. The total duration per patient is approximately 7 months (approximately 1 month run-in period followed by 6 months active treatment).

Being tested
intrathecal baclofen
Keywords
Severe spasticity in post-stroke patients
Medical subject headings
Muscle Spasticity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • intrathecal baclofenDrug

    ITB test, implant, 6 months follow-up

Study groups in NCT01032239
Study groupRoleWhat they receive
ITB therapyActive comparatorIntrathecal Baclofen therapy (Intrathecal baclofen + implantable pump)
Receives: Drug: intrathecal baclofen
Best Medical Treatment (BMT)No interventionUse one or a combination oral antispastic medication.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6

    AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed.

    Change= AS at month 6 - AS at baseline.

    Measured: Baseline and month 6

Secondary outcomes (11)
  1. Change in Average Ashworth Scale (AS) in Affected Upper Extremities From Baseline to Month 6

    AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the upper extremities were assessed: wrist flexors, elbow flexors, elbow extensors, shoulder abductors and shoulder adductors. Average AS was calculated as the average of AS scores of the 5 muscles of the affected lower extremities. Change in average AS in affected upper extremities from baseline to month 6 between ITB and BMT arm was assessed.

    Change= AS at month 6 - AS at baseline.

    Measured: Baseline and month 6

  2. Change in Functional Independence Measure (FIM) Score From Baseline to Month 6

    FIM contains 18 items composed of 13 motor tasks and 5 cognitive tasks. Tasks are rated on a 7-point ordinal scale that ranges from total assistance (or complete dependence) to complete independence. Ratings should reflect actual observed performance, not capability. Total score ranges from 18 (lowest) to 126 (highest) level of independence. Change in FIM total score from baseline to month 6 between ITB and BMT arm was assessed. Change=FIM score at month 6 - FIM score at baseline.

    Measured: Baseline and month 6

  3. Change in Average 10 Meter Time Walking Test (10MTWT) From Baseline to Month 6

    Change in average 10MTWT from baseline to month 6 beetween ITB and BMT arm. Change=10MTWT at month 6 - 10MTWT at baseline

    Measured: Baseline and month 6

  4. Number of Participants Who Were Able to Transfer From the Wheelchair to Bed Without Human Assistance

    Patient was asked to transfer from the wheelchair to bed without human assistance. High level functional patient (HLP) could transfer. Low level functional patient (LLP) was not able to transfer. Comparison of the number and percentage of HLP and LLP between ITB and BMT arms was evaluated.

    Measured: baseline, month 3, month 6

  5. Change in Numeric Pain Rating Scale (NPRS) From Baseline to Month 6

    NPRS is designed to assess the level of pain a patient is feeling at a point in time. The following questions has been presented to patients: What is your actual spasticity-related or spasm-related pain? What was your least spasticity-related or spasm-related pain during the last week? What was your worst spasticity-related or spasm-related pain during the last week? The patient indicated how much pain he is feeling on a scale from 0 to 10. A score of 0 (zero) is "no pain" while a score of 10 (ten) is "worst possible pain". Change in NPRS related to actual, least or worst pain from baseline to month 6 between ITB and BMT arm was assessed. Change=NPRS at month 6 - NPRS at baseline.

    Measured: Baseline and month 6

  6. Number of Participants Who Achieved Their Primary Therapeutic Goal Assessed With the Goal Attainment Scale (GAS)

    GAS is designed to measure the achievement of treatment goals using the following 6 levels of achievement: worse than start (-3), much less than expected (-2), somewhat less than expected (-1), as expected (0), somewhat more than expected (+1), much more than expected (+2). The primary therapy goal and the criteria for the levels of achievement was defined by the medical team together with the patient and his/her family/legal representative/caregiver at the first day of the study. The number and percentage of patients who achieved the therapeutic goal at Month 6 was compared between the ITB and BMT arm.

    Measured: month 6

  7. Change in Euro QoL Group-5 Dimensional, 3 Level Version (EQ-5D-3L) From Baseline to Month 6

    The EQ-5D-3L is a generic measure of health status consisting in the EQ-5D-3L descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system is characterized on five dimensions: mobility, self-care, ability to undertake usual activities, pain and anxiety/depression. Patients were asked to indicate their level of health on each dimension using one of three levels: "no health problems", "moderate health problems", and "severe health problems". Responses from the questionnaire were converted to a single health index utility score; this ranges from -0.595 to 1. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100 where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). Change in EQ-5D-3L utility score and VAS score from baseline to month 6 between ITB and BMT arm were assessed. Change=EQ-5D-3L utility or VAS score at month 6 - EQ-5D-3L utility or VAS score.

    Measured: Baseline and month 6

  8. Change in SF-12 (12-item Short Form) From Baseline to Month 6

    The SF-12 is generic assessment of health-related quality of life, which evaluates 8 health dimensions (physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health). Subscale scores for each dimension were aggregated into summary scores for physical (PCS) and mental health (MCS) components (ranging from 0 to 100, with higher scores indicating better health). Changes in the PCS and MCS from baseline to Month 6 were both compared between the BMT and ITB arms. Change=SF-12 score at month 6 - SF-12 score at baseline.

    Measured: Baseline and month 6

  9. Change in Stroke Specific Quality of Life (SS-QoL ) From Baseline to Month 6

    SS-QoL questionnaire is a self-assessed quality of life questionnaire specifically designed for post-stroke patients. It evaluates 49 items across 12-domains: personality, energy, language, mobility, vision, upper extremity function, thinking, mood, work/productivity, self-care, and family and social roles. Each item is rated on a 5-point Likert Scale, measuring either positive or negative response to a statement. Summary score is composed of an unweighted average of the 12 domain scores, with higher scores indicating better QoL. Total score ranges from 1 to 5. Change in SS-QoL summary score from baseline to month 6 between ITB and BMT arm was assessed.

    Change=SS-QoL score at month 6 - SS-QoL score at baseline.

    Measured: Baseline and month 6

  10. Therapy Satisfaction

    Patients were presented with two statements ("I am satisfied with the reduction in spasticity provided by my treatment", and "I would recommend this therapy to a friend"). They agreed, disagreed or were neutral with the statements.

    Measured: month 6

  11. Healthcare Resource Utilization

    Number of patients with healthcare professional contacts outside of study visits in the ITB and BMT between baseline and months 6

    Measured: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Dec 2009 (estimated)
  2. Study startNov 2009
  3. Primary completionSep 2016
  4. Study completionSep 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
61 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01032239
Sponsor's protocol ID
1.02.7001
Acronym
SISTERS
Status last verified
Jan 2018
First submitted
7 Dec 2009
Last updated
15 Feb 2018
Data monitoring committee
Yes

Publications

  • Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, Wissel J, Zampolini M, Abouihia A, Calabrese A, Saltuari L. Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. Stroke. 2018 Sep;49(9):2129-2137. doi: 10.1161/STROKEAHA.118.022255.

    PubMed 30354975
  • Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, Wissel J, Zampolini M, Abouihia A, Berthuy N, Calabrese A, Loven M, Saltuari L. Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):642-650. doi: 10.1136/jnnp-2017-317021. Epub 2018 Jan 11.

    PubMed 29326296

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing intrathecal baclofen in people with Severe Spasticity, run by MedtronicNeuro at 25 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 25 sites in United States, Germany, Belgium, Austria, Italy and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Feb 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 (time frame: Baseline and month 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01032239, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2018; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in